世界のプロテオミクス市場は、2025年に36482百万米ドルと算定されており、2026年には39132百万米ドルとなる見通しです。2026年から2032年の期間においては年平均成長率（CAGR）9.5%で推移し、2032年には67271百万米ドルに達すると予測されています。

本レポートは、プロテオミクスメーカー、新規参入企業、および業界バリューチェーン全体の企業に対し、市場全体およびサブセグメント別の収益、生産量、平均価格に関する情報を、企業別、タイプ別、用途別、地域別に提供します。
世界のプロテオミクス市場について、定量的・定性的分析を交えた包括的な概観を提供し、企業関係者が成長戦略の策定、競争環境の評価、現行市場における自社の位置付けの分析、プロテオミクスに関する情報に基づいたビジネス判断を行うことを支援します。プロテオミクス市場の規模、推定値及び予測値の観点から提示し、2025年を基準年として、2021年から2032年までの過去データ及び予測データを収録しております。

報告対象範囲
売上高・数量予測、企業シェア、競争環境、成長要因および市場トレンド

市場セグメンテーション
企業一覧
Thermo Fisher Scientific
Agilent Technologies
Merck KGaA
Danaher
Waters
Bio-Rad Laboratories
Bruker
Roche
PerkinElmer
Promega
Shimazdu
Talus Bio
G-Biosciences
Biodesix
Applied Biomics
Arbor Vita
Biosero
Illumina
Bio-Techne (Merck KGaA)
Qiagen
Sartorius
Charles River Laboratories
CellCarta
PTM BIO
Standard Biotools
Labcorp
BostonGene
APTBIO
Cell Signaling Technology (CST)
Inotiv
Bruker Spatial Biology
BGI Genomics
Biognosys
Crown Bioscience
Eurofins Scientific
Charles River Laboratories
Discovery Life Sciences
Shanghai OE Biotech
Biodesix
Novogene
OmicScouts (Momentum Biotechnologies)
Lc-Bio Technologies
Creative Proteomics
Metware Biotechnology
GENEWIZ (Azenta Life Sciences)
CDI Labs
Evotec
MS Bioworks
Shanghai Bioprofile
MtoZ-Biolabs


タイプ別
Proteomics Instruments
Proteomics Reagents
Proteomics Services
Proteomics Software


用途別
Clinical Diagnostics
Drug Discovery
Others


製品カテゴリー


市場セグメント
Universities and Research Institutes
Hospitals
Pharmaceutical Companies
Others

地域別
北米（アメリカ、カナダ、メキシコ）
欧州（ドイツ、フランス、イギリス、イタリアなど）
アジア太平洋（中国、日本、韓国、東南アジア、インドなど）
南米（ブラジルなど）
中東・アフリカ（トルコ、GCC諸国、アフリカなど）
本レポートは、世界のプロテオミクス市場を包括的にセグメント化しております。地域別市場規模、タイプ別、用途別、企業別の市場規模も提供されます。より深い洞察を得るため、競争環境、主要競合他社、それぞれの市場順位をプロファイリングし、技術動向や新製品開発についても論じております。

本レポートの構成
第1章：プロテオミクスの定義および調査範囲を明確化し、市場セグメント（タイプ別、用途別など）の概要を提示します。各セグメントの市場規模と将来の成長可能性を網羅し、現在の市場状況の概要を提供するとともに、短期・中期・長期の発展トレンドを分析します
第2章：プロテオミクスメーカーの競争環境について、価格、生産量、価値ベースの市場シェア、最新の開発計画、合併・買収情報を含め詳細に分析します
第3章：プロテオミクスの生産量／生産高および価値を地域・国別に検証し、今後6年間の各地域の市場規模と成長可能性について定量的な評価を提供します
第4章：地域および国レベルでのプロテオミクスの消費動向を分析します。各地域および主要国における市場規模と成長可能性を定量化し、市場開発状況、見通し、対応可能な市場規模、国内生産量を概説します
第5章：プロテオミクスに基づくタイプ別市場セグメントの構造を整理し、各セグメントの市場規模と成長ポテンシャルを明確化することで、企業・投資家によるブルーオーシャン機会の発見を支援します
第6章：用途別にプロテオミクスの市場セグメントを整理し、各分野の市場規模、成長ポテンシャル、需要拡大余地を提示することで、下流市場における有望な参入機会や競争優位の確立に向けた判断材料を提供します
第7章：プロテオミクスの主要プレイヤーを分析し、主要企業の基本情報（製品生産量／生産高、価値、価格、粗利益率、製品ポートフォリオ／新製品導入、最近の動向）を詳細に説明します
第8章：プロテオミクスの上流および下流セグメントを含む業界バリューチェーンをレビューします
第9章：プロテオミクス市場の動向と最新トレンドについて議論します。これには、メーカーにとっての推進要因、制約要因、課題、リスク、米国関税、関連政策分析が含まれます
第10章：主な調査結果と結論をまとめます
第11章：付録

The global Proteomics market was valued at US$ 36482 million in 2025 and is anticipated to reach US$ 67271 million by 2032, at a CAGR of 9.5% from 2026 to 2032.

Proteomics is an advanced life science analytical discipline that systematically studies the complete set of proteins within biological systems, including protein identification, quantification, structural characterization, functional regulation, post-translational modifications, and protein interaction networks. As a critical bridge between genomic information and biological phenotypes, proteomics analyzes protein expression patterns and molecular changes in cells, tissues, blood, and other biological samples to reveal disease mechanisms, biological pathways, and therapeutic responses.

Modern proteomics relies on high-resolution mass spectrometry, liquid chromatography-tandem mass spectrometry (LC-MS/MS), affinity-based protein profiling, multiplex protein analysis platforms, single-cell proteomics, and spatial proteomics technologies to enable accurate detection and interpretation of hundreds to tens of thousands of proteins. Driven by precision medicine, biopharmaceutical innovation, oncology research, immunotherapy development, and AI-enabled biological data analysis, proteomics has evolved from a research methodology into an integrated industrial ecosystem covering analytical instruments, reagents and consumables, bioinformatics software, and specialized testing services. Its strategic importance lies in providing molecular insights for drug target discovery, biomarker identification, clinical diagnostics, and personalized therapeutic development.

The proteomics industry operates under an integrated business model combining advanced analytical instrument manufacturing, specialized reagent and consumable production, bioinformatics software development, and professional proteomics services. The upstream value chain includes suppliers of mass spectrometry components, optical systems, chromatography modules, biochemical reagents, antibodies, protein standards, and microarray materials. The midstream sector consists of proteomics instrument manufacturers, technology platform providers, software developers, and contract research organizations (CROs). The downstream market includes pharmaceutical companies, biotechnology firms, academic institutions, hospitals, diagnostic companies, and industrial biotechnology users.

From a commercial perspective, the proteomics industry demonstrates strong platform-based characteristics. High-end mass spectrometers and multiplex protein analysis systems typically adopt a business model combining instrument sales with recurring consumable revenues and maintenance services. Reagents and consumables generate higher recurring margins due to continuous demand and technological specialization. Software and bioinformatics platforms create additional value through algorithms, databases, and data interpretation capabilities, while CRO services improve efficiency through large-scale sample processing.

Overall, proteomics businesses generally achieve attractive gross margins. High-end analytical instruments and innovative protein analysis platforms typically generate gross margins of approximately 50%-70% due to significant technological barriers and customer qualification requirements. Specialized reagents, antibodies, and protein assay consumables may achieve gross margins of around 60%-80% because of recurring purchasing patterns and intellectual property advantages. Standardized testing services face stronger competition and generally maintain margins of approximately 30%-50%. Leading companies improve profitability through integrated ecosystems combining instruments, consumables, software, and services.

The proteomics market is entering a new stage of accelerated transition from academic research applications toward clinical translation and industrial commercialization. Growing demand for precision medicine, increasing investment in biopharmaceutical innovation, and deeper investigation of complex diseases are positioning proteomics as a critical technology platform in life sciences. Rising research activities in oncology, immunology, and neurodegenerative diseases continue to stimulate demand for highly sensitive, high-throughput, and multidimensional protein analysis technologies. Pharmaceutical companies are increasingly adopting proteomics for target discovery, mechanism-of-action studies, and companion diagnostics development to improve R&D efficiency and reduce development risks.

Despite strong growth prospects, the proteomics industry faces challenges including high technological complexity, expensive analytical platforms, sophisticated data interpretation requirements, and limited standardization across different workflows. Advanced mass spectrometry systems and next-generation protein analysis platforms require continuous investment in research and development. Furthermore, clinical validation, regulatory approval processes, and dependence on research funding cycles may create market uncertainties. Companies need to continuously strengthen technological innovation, automation capabilities, and bioinformatics expertise to maintain sustainable competitiveness.

Future demand for proteomics technologies will increasingly shift toward high-throughput analysis, clinical applications, and AI-driven biological interpretation. Pharmaceutical and biotechnology companies are expected to remain major growth engines by utilizing proteomics for innovative drug discovery and precision therapeutic development. Hospitals and diagnostic organizations are gradually exploring proteomics-based solutions for early disease detection, risk prediction, and companion diagnostics. Meanwhile, academic research will continue advancing single-cell proteomics, spatial proteomics, and multi-omics integration. With deeper integration of artificial intelligence, big data analytics, and automated laboratory platforms, proteomics is expected to become a fundamental infrastructure supporting future biomedical innovation and healthcare transformation.

This report delivers a comprehensive overview of the global Proteomics market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Proteomics. The Proteomics market size, estimates, and forecasts are provided in terms of revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.

The report segments the global Proteomics market comprehensively. Regional market sizes by Type, by Application, by Proteomics Type, and by player are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.

This report will assist Proteomics manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Market Segmentation
By Company
Thermo Fisher Scientific
Agilent Technologies
Merck KGaA
Danaher
Waters
Bio-Rad Laboratories
Bruker
Roche
PerkinElmer
Promega
Shimazdu
Talus Bio
G-Biosciences
Biodesix
Applied Biomics
Arbor Vita
Biosero
Illumina
Bio-Techne (Merck KGaA)
Qiagen
Sartorius
Charles River Laboratories
CellCarta
PTM BIO
Standard Biotools
Labcorp
BostonGene
APTBIO
Cell Signaling Technology (CST)
Inotiv
Bruker Spatial Biology
BGI Genomics
Biognosys
Crown Bioscience
Eurofins Scientific
Charles River Laboratories
Discovery Life Sciences
Shanghai OE Biotech
Biodesix
Novogene
OmicScouts (Momentum Biotechnologies)
Lc-Bio Technologies
Creative Proteomics
Metware Biotechnology
GENEWIZ (Azenta Life Sciences)
CDI Labs
Evotec
MS Bioworks
Shanghai Bioprofile
MtoZ-Biolabs

Segment by Type
Proteomics Instruments
Proteomics Reagents
Proteomics Services
Proteomics Software

Segment by Proteomics Type
Bulk Proteomics
Targeted/Affinity Preteomics
Spatial Proteomics
Single-Molecule Proteomics
Others

Segment by End User
Universities and Research Institutes
Hospitals
Pharmaceutical Companies
Others

Segment by Application
Clinical Diagnostics
Drug Discovery
Others

By Region
North America
U.S.
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia & New Zealand
Rest of Asia
Europe
Germany
France
U.K.
Italy
Ireland
Russia
Rest of Europe
Latin America
Mexico
Brazil
Argentina
Rest of Latin America
Middle East & Africa
Israel
United Arab Emirates (UAE)
Saudi Arabia
Rest of MEA

Chapter Outline
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, by Proteomics Type, etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Summarizes global and regional market size and outlines market dynamics and recent developments, including key drivers, restraints, challenges and risks for industry participants, and relevant policy analysis.
Chapter 3: Provides a detailed view of the competitive landscape for Proteomics companies, covering revenue share, development plans, and mergers and acquisitions.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify blue-ocean opportunities.
Chapter 5: Analyzes segments by Application, detailing the size and growth potential of each downstream segment to help readers identify blue-ocean opportunities.
Chapter 6–10: Regional deep dives (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) broken down by country. Each chapter quantifies market size and growth potential by region and key countries, and outlines market development, outlook, addressable space, and capacity.
Chapter 11: Profiles key players, presenting essential information on leading companies, including product/ service offerings, revenue, gross margin, product introductions/portfolios, recent developments, etc.
Chapter 12: Key findings and conclusions of the report.

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Proteomics Market Size Growth Rate by Type: 2021 vs 2025 vs 2032
1.2.2 Proteomics Instruments
1.2.3 Proteomics Reagents
1.2.4 Proteomics Services
1.2.5 Proteomics Software
1.3 Market by Proteomics Type
1.3.1 Global Proteomics Market Size Growth Rate by Proteomics Type: 2021 vs 2025 vs 2032
1.3.2 Bulk Proteomics
1.3.3 Targeted/Affinity Preteomics
1.3.4 Spatial Proteomics
1.3.5 Single-Molecule Proteomics
1.3.6 Others
1.4 Market by End User
1.4.1 Global Proteomics Market Size Growth Rate by End User: 2021 vs 2025 vs 2032
1.4.2 Universities and Research Institutes
1.4.3 Hospitals
1.4.4 Pharmaceutical Companies
1.4.5 Others
1.5 Market by Application
1.5.1 Global Proteomics Market Growth by Application: 2021 vs 2025 vs 2032
1.5.2 Clinical Diagnostics
1.5.3 Drug Discovery
1.5.4 Others
1.6 Assumptions and Limitations
1.7 Study Objectives
1.8 Years Considered

2 Global Growth Trends
2.1 Global Proteomics Market Perspective (2021–2032)
2.2 Global Proteomics Growth Trends by Region
2.2.1 Global Proteomics Market Size by Region: 2021 vs 2025 vs 2032
2.2.2 Proteomics Historic Market Size by Region (2021–2026)
2.2.3 Proteomics Forecasted Market Size by Region (2027–2032)
2.3 Proteomics Market Dynamics
2.3.1 Proteomics Industry Trends
2.3.2 Proteomics Market Drivers
2.3.3 Proteomics Market Challenges
2.3.4 Proteomics Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Proteomics Players by Revenue
3.1.1 Global Top Proteomics Players by Revenue (2021–2026)
3.1.2 Global Proteomics Revenue Market Share by Players (2021–2026)
3.2 Global Top Proteomics Players Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
3.3 Global Key Players Ranking by Proteomics Revenue
3.4 Global Proteomics Market Concentration Ratio
3.4.1 Global Proteomics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Proteomics Revenue in 2025
3.5 Global Key Players of Proteomics Head Offices and Areas Served
3.6 Global Key Players of Proteomics, Products and Applications
3.7 Global Key Players of Proteomics, Date of General Availability (GA)
3.8 Mergers and Acquisitions, Expansion Plans

4 Proteomics Breakdown Data by Type
4.1 Global Proteomics Historic Market Size by Type (2021–2026)
4.2 Global Proteomics Forecasted Market Size by Type (2027–2032)

5 Proteomics Breakdown Data by Application
5.1 Global Proteomics Historic Market Size by Application (2021–2026)
5.2 Global Proteomics Forecasted Market Size by Application (2027–2032)

6 North America
6.1 North America Proteomics Market Size (2021–2032)
6.2 North America Proteomics Market Growth Rate by Country: 2021 vs 2025 vs 2032
6.3 North America Proteomics Market Size by Country (2021–2026)
6.4 North America Proteomics Market Size by Country (2027–2032)
6.5 United States
6.6 Canada

7 Europe
7.1 Europe Proteomics Market Size (2021–2032)
7.2 Europe Proteomics Market Growth Rate by Country: 2021 vs 2025 vs 2032
7.3 Europe Proteomics Market Size by Country (2021–2026)
7.4 Europe Proteomics Market Size by Country (2027–2032)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Ireland

8 Asia-Pacific
8.1 Asia-Pacific Proteomics Market Size (2021–2032)
8.2 Asia-Pacific Proteomics Market Growth Rate by Region: 2021 vs 2025 vs 2032
8.3 Asia-Pacific Proteomics Market Size by Region (2021–2026)
8.4 Asia-Pacific Proteomics Market Size by Region (2027–2032)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia & New Zealand

9 Latin America
9.1 Latin America Proteomics Market Size (2021–2032)
9.2 Latin America Proteomics Market Growth Rate by Country: 2021 vs 2025 vs 2032
9.3 Latin America Proteomics Market Size by Country (2021–2026)
9.4 Latin America Proteomics Market Size by Country (2027–2032)
9.5 Mexico
9.6 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Proteomics Market Size (2021–2032)
10.2 Middle East & Africa Proteomics Market Growth Rate by Country: 2021 vs 2025 vs 2032
10.3 Middle East & Africa Proteomics Market Size by Country (2021–2026)
10.4 Middle East & Africa Proteomics Market Size by Country (2027–2032)
10.5 Israel
10.6 Saudi Arabia
10.7 UAE

11 Key Players Profiles
11.1 Thermo Fisher Scientific
11.1.1 Thermo Fisher Scientific Company Details
11.1.2 Thermo Fisher Scientific Business Overview
11.1.3 Thermo Fisher Scientific Proteomics Introduction
11.1.4 Thermo Fisher Scientific Revenue in Proteomics Business (2021–2026)
11.1.5 Thermo Fisher Scientific Recent Development
11.2 Agilent Technologies
11.2.1 Agilent Technologies Company Details
11.2.2 Agilent Technologies Business Overview
11.2.3 Agilent Technologies Proteomics Introduction
11.2.4 Agilent Technologies Revenue in Proteomics Business (2021–2026)
11.2.5 Agilent Technologies Recent Development
11.3 Merck KGaA
11.3.1 Merck KGaA Company Details
11.3.2 Merck KGaA Business Overview
11.3.3 Merck KGaA Proteomics Introduction
11.3.4 Merck KGaA Revenue in Proteomics Business (2021–2026)
11.3.5 Merck KGaA Recent Development
11.4 Danaher
11.4.1 Danaher Company Details
11.4.2 Danaher Business Overview
11.4.3 Danaher Proteomics Introduction
11.4.4 Danaher Revenue in Proteomics Business (2021–2026)
11.4.5 Danaher Recent Development
11.5 Waters
11.5.1 Waters Company Details
11.5.2 Waters Business Overview
11.5.3 Waters Proteomics Introduction
11.5.4 Waters Revenue in Proteomics Business (2021–2026)
11.5.5 Waters Recent Development
11.6 Bio-Rad Laboratories
11.6.1 Bio-Rad Laboratories Company Details
11.6.2 Bio-Rad Laboratories Business Overview
11.6.3 Bio-Rad Laboratories Proteomics Introduction
11.6.4 Bio-Rad Laboratories Revenue in Proteomics Business (2021–2026)
11.6.5 Bio-Rad Laboratories Recent Development
11.7 Bruker
11.7.1 Bruker Company Details
11.7.2 Bruker Business Overview
11.7.3 Bruker Proteomics Introduction
11.7.4 Bruker Revenue in Proteomics Business (2021–2026)
11.7.5 Bruker Recent Development
11.8 Roche
11.8.1 Roche Company Details
11.8.2 Roche Business Overview
11.8.3 Roche Proteomics Introduction
11.8.4 Roche Revenue in Proteomics Business (2021–2026)
11.8.5 Roche Recent Development
11.9 PerkinElmer
11.9.1 PerkinElmer Company Details
11.9.2 PerkinElmer Business Overview
11.9.3 PerkinElmer Proteomics Introduction
11.9.4 PerkinElmer Revenue in Proteomics Business (2021–2026)
11.9.5 PerkinElmer Recent Development
11.10 Promega
11.10.1 Promega Company Details
11.10.2 Promega Business Overview
11.10.3 Promega Proteomics Introduction
11.10.4 Promega Revenue in Proteomics Business (2021–2026)
11.10.5 Promega Recent Development
11.11 Shimazdu
11.11.1 Shimazdu Company Details
11.11.2 Shimazdu Business Overview
11.11.3 Shimazdu Proteomics Introduction
11.11.4 Shimazdu Revenue in Proteomics Business (2021–2026)
11.11.5 Shimazdu Recent Development
11.12 Talus Bio
11.12.1 Talus Bio Company Details
11.12.2 Talus Bio Business Overview
11.12.3 Talus Bio Proteomics Introduction
11.12.4 Talus Bio Revenue in Proteomics Business (2021–2026)
11.12.5 Talus Bio Recent Development
11.13 G-Biosciences
11.13.1 G-Biosciences Company Details
11.13.2 G-Biosciences Business Overview
11.13.3 G-Biosciences Proteomics Introduction
11.13.4 G-Biosciences Revenue in Proteomics Business (2021–2026)
11.13.5 G-Biosciences Recent Development
11.14 Biodesix
11.14.1 Biodesix Company Details
11.14.2 Biodesix Business Overview
11.14.3 Biodesix Proteomics Introduction
11.14.4 Biodesix Revenue in Proteomics Business (2021–2026)
11.14.5 Biodesix Recent Development
11.15 Applied Biomics
11.15.1 Applied Biomics Company Details
11.15.2 Applied Biomics Business Overview
11.15.3 Applied Biomics Proteomics Introduction
11.15.4 Applied Biomics Revenue in Proteomics Business (2021–2026)
11.15.5 Applied Biomics Recent Development
11.16 Arbor Vita
11.16.1 Arbor Vita Company Details
11.16.2 Arbor Vita Business Overview
11.16.3 Arbor Vita Proteomics Introduction
11.16.4 Arbor Vita Revenue in Proteomics Business (2021–2026)
11.16.5 Arbor Vita Recent Development
11.17 Biosero
11.17.1 Biosero Company Details
11.17.2 Biosero Business Overview
11.17.3 Biosero Proteomics Introduction
11.17.4 Biosero Revenue in Proteomics Business (2021–2026)
11.17.5 Biosero Recent Development
11.18 Illumina
11.18.1 Illumina Company Details
11.18.2 Illumina Business Overview
11.18.3 Illumina Proteomics Introduction
11.18.4 Illumina Revenue in Proteomics Business (2021–2026)
11.18.5 Illumina Recent Development
11.19 Bio-Techne (Merck KGaA)
11.19.1 Bio-Techne (Merck KGaA) Company Details
11.19.2 Bio-Techne (Merck KGaA) Business Overview
11.19.3 Bio-Techne (Merck KGaA) Proteomics Introduction
11.19.4 Bio-Techne (Merck KGaA) Revenue in Proteomics Business (2021–2026)
11.19.5 Bio-Techne (Merck KGaA) Recent Development
11.20 Qiagen
11.20.1 Qiagen Company Details
11.20.2 Qiagen Business Overview
11.20.3 Qiagen Proteomics Introduction
11.20.4 Qiagen Revenue in Proteomics Business (2021–2026)
11.20.5 Qiagen Recent Development
11.21 Sartorius
11.21.1 Sartorius Company Details
11.21.2 Sartorius Business Overview
11.21.3 Sartorius Proteomics Introduction
11.21.4 Sartorius Revenue in Proteomics Business (2021–2026)
11.21.5 Sartorius Recent Development
11.22 Charles River Laboratories
11.22.1 Charles River Laboratories Company Details
11.22.2 Charles River Laboratories Business Overview
11.22.3 Charles River Laboratories Proteomics Introduction
11.22.4 Charles River Laboratories Revenue in Proteomics Business (2021–2026)
11.22.5 Charles River Laboratories Recent Development
11.23 CellCarta
11.23.1 CellCarta Company Details
11.23.2 CellCarta Business Overview
11.23.3 CellCarta Proteomics Introduction
11.23.4 CellCarta Revenue in Proteomics Business (2021–2026)
11.23.5 CellCarta Recent Development
11.24 PTM BIO
11.24.1 PTM BIO Company Details
11.24.2 PTM BIO Business Overview
11.24.3 PTM BIO Proteomics Introduction
11.24.4 PTM BIO Revenue in Proteomics Business (2021–2026)
11.24.5 PTM BIO Recent Development
11.25 Standard Biotools
11.25.1 Standard Biotools Company Details
11.25.2 Standard Biotools Business Overview
11.25.3 Standard Biotools Proteomics Introduction
11.25.4 Standard Biotools Revenue in Proteomics Business (2021–2026)
11.25.5 Standard Biotools Recent Development
11.26 Labcorp
11.26.1 Labcorp Company Details
11.26.2 Labcorp Business Overview
11.26.3 Labcorp Proteomics Introduction
11.26.4 Labcorp Revenue in Proteomics Business (2021–2026)
11.26.5 Labcorp Recent Development
11.27 BostonGene
11.27.1 BostonGene Company Details
11.27.2 BostonGene Business Overview
11.27.3 BostonGene Proteomics Introduction
11.27.4 BostonGene Revenue in Proteomics Business (2021–2026)
11.27.5 BostonGene Recent Development
11.28 APTBIO
11.28.1 APTBIO Company Details
11.28.2 APTBIO Business Overview
11.28.3 APTBIO Proteomics Introduction
11.28.4 APTBIO Revenue in Proteomics Business (2021–2026)
11.28.5 APTBIO Recent Development
11.29 Cell Signaling Technology (CST)
11.29.1 Cell Signaling Technology (CST) Company Details
11.29.2 Cell Signaling Technology (CST) Business Overview
11.29.3 Cell Signaling Technology (CST) Proteomics Introduction
11.29.4 Cell Signaling Technology (CST) Revenue in Proteomics Business (2021–2026)
11.29.5 Cell Signaling Technology (CST) Recent Development
11.30 Inotiv
11.30.1 Inotiv Company Details
11.30.2 Inotiv Business Overview
11.30.3 Inotiv Proteomics Introduction
11.30.4 Inotiv Revenue in Proteomics Business (2021–2026)
11.30.5 Inotiv Recent Development
11.31 Bruker Spatial Biology
11.31.1 Bruker Spatial Biology Company Details
11.31.2 Bruker Spatial Biology Business Overview
11.31.3 Bruker Spatial Biology Proteomics Introduction
11.31.4 Bruker Spatial Biology Revenue in Proteomics Business (2021–2026)
11.31.5 Bruker Spatial Biology Recent Development
11.32 BGI Genomics
11.32.1 BGI Genomics Company Details
11.32.2 BGI Genomics Business Overview
11.32.3 BGI Genomics Proteomics Introduction
11.32.4 BGI Genomics Revenue in Proteomics Business (2021–2026)
11.32.5 BGI Genomics Recent Development
11.33 Biognosys
11.33.1 Biognosys Company Details
11.33.2 Biognosys Business Overview
11.33.3 Biognosys Proteomics Introduction
11.33.4 Biognosys Revenue in Proteomics Business (2021–2026)
11.33.5 Biognosys Recent Development
11.34 Crown Bioscience
11.34.1 Crown Bioscience Company Details
11.34.2 Crown Bioscience Business Overview
11.34.3 Crown Bioscience Proteomics Introduction
11.34.4 Crown Bioscience Revenue in Proteomics Business (2021–2026)
11.34.5 Crown Bioscience Recent Development
11.35 Eurofins Scientific
11.35.1 Eurofins Scientific Company Details
11.35.2 Eurofins Scientific Business Overview
11.35.3 Eurofins Scientific Proteomics Introduction
11.35.4 Eurofins Scientific Revenue in Proteomics Business (2021–2026)
11.35.5 Eurofins Scientific Recent Development
11.36 Charles River Laboratories
11.36.1 Charles River Laboratories Company Details
11.36.2 Charles River Laboratories Business Overview
11.36.3 Charles River Laboratories Proteomics Introduction
11.36.4 Charles River Laboratories Revenue in Proteomics Business (2021–2026)
11.36.5 Charles River Laboratories Recent Development
11.37 Discovery Life Sciences
11.37.1 Discovery Life Sciences Company Details
11.37.2 Discovery Life Sciences Business Overview
11.37.3 Discovery Life Sciences Proteomics Introduction
11.37.4 Discovery Life Sciences Revenue in Proteomics Business (2021–2026)
11.37.5 Discovery Life Sciences Recent Development
11.38 Shanghai OE Biotech
11.38.1 Shanghai OE Biotech Company Details
11.38.2 Shanghai OE Biotech Business Overview
11.38.3 Shanghai OE Biotech Proteomics Introduction
11.38.4 Shanghai OE Biotech Revenue in Proteomics Business (2021–2026)
11.38.5 Shanghai OE Biotech Recent Development
11.39 Biodesix
11.39.1 Biodesix Company Details
11.39.2 Biodesix Business Overview
11.39.3 Biodesix Proteomics Introduction
11.39.4 Biodesix Revenue in Proteomics Business (2021–2026)
11.39.5 Biodesix Recent Development
11.40 Novogene
11.40.1 Novogene Company Details
11.40.2 Novogene Business Overview
11.40.3 Novogene Proteomics Introduction
11.40.4 Novogene Revenue in Proteomics Business (2021–2026)
11.40.5 Novogene Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer